(NYSE American: OGEN) (“the “Company”) a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its targeted ...
A 69-year-old retired radio host and disc jockey was referred to the neuro-ophthalmology service for evaluation of a 3-month ...
Northwestern University recently awarded more than $2 million to eight innovative projects through the Pat & Shirley Ryan Family Research Acceleration ...
Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Austra ...
Parkinson's disease does more than cause tremor and trouble walking. It can also affect sleep, smell, digestion and even ...
Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...
New clinical trial data suggest vidofludimus calcium can target key mechanisms underlying progressive multiple sclerosis.
Issues including resolution, portability and deployment need to be addressed for low-field MRI to be effective in underserved ...
The latest round of strategic seed funding is propelling innovations in imaging, brain health, autoimmune therapies, and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results